News

Inhibikase Receives Orphan-Drug Designation for risvodetinib in Multiple System Atrophy

1 Mins read

Shares of Inhibikase Therapeutics surged in premarket trading on Wednesday following the company’s recent acquisition of orphan-drug designation from the U.S. Food and Drug Administration (FDA) for its flagship program, risvodetinib. This medical breakthrough is specifically aimed at treating multiple system atrophy (MSA), a rare and incurable neurological disease known for its degenerative effect on certain brain regions.

At present, there are no FDA-approved therapeutic interventions available to address the symptoms or modify the progression of MSA. The orphan-drug program by the FDA grants special recognition to drugs and biologics designed to tackle diseases and disorders that impact fewer than 200,000 individuals in the United States. Moreover, this designation provides the drugs with an extended period of marketing exclusivity, protecting them against potential competitors.

Inhibikase Therapeutics is currently focused on advancing its animal-model studies to explore the therapeutic potential of risvodetinib in blocking the progression of MSA as well as potentially reversing functional loss associated with this debilitating neurological condition.

The shares of Inhibikase skyrocketed by 22% in premarket trading, reaching $1.71 per share from their previous closing price of $1.40.

Related posts
News

Trump threatens to pull support for Argentina if its politics move leftward

5 Mins read
President Donald Trump greets Argentina’s President Javier Milei at the White House, Tuesday, Oct. 14, 2025, in Washington.Trending NowBest Forex Trading Robots…
News

Trump news at a glance: President declares 'peace in the Middle East' despite many barriers remaining

3 Mins read
Trump news at a glance: President declares ‘peace in the Middle East’ despite many barriers remainingTrending NowBest Forex Trading Robots To Invest…
News

Binance Founder CZ Clarifies BNB Trade Activity and Market Strategy

1 Mins read
On October 12, Binance’s founder Changpeng Zhao confirmed via X that BNB lacks market makers, highlighting its deflationary nature and community-driven development….

Leave a Reply

Your email address will not be published. Required fields are marked *

40 − = 35